In recent years, most human beings are affected by a disease called cancer. Early-stage detection of cancer leads to successful treatment for cancer patients. However, the rapid growth of Nano-HAp technology provides high precision, specificity, sensitivity, and multiplexed measurement to detect cancer cells with biomarkers using in-vivo and in-vitro imaging. Nano-HAp develops nanomedicine products to improve therapies against cancer. An efficient systematic pharmaceutical treatment of cancer tumors is a cytotoxic chemotherapy drug developed at a local drug delivery site. In this paper, nanoparticles and targeted systems have been investigated with clinical data to create a nano HAp schema for cancer-affected patients. Substantiate that anti-Cancer DOX (Doxorubicin) and cornerstone drug therapy of osteosarcoma and carcinoma treatment, shows a chemical reaction to Hydroxyapatite (HAp) of nano-HAp (nHAp), PEG (Polyethylene glycol), PBS solution (Phosphate Buffer Saline), FBS serum (Fetal Bovine Serum), (Sulphate doped HAp) nanosphere via the liposome of osteosarcoma and carcinoma cells where the environment creates and binds the nanoparticle drugs to release the drugs in the mitochondria and cytotoxicity in the HAp system delivery. In addition, chemotherapy and nHAp could be used as an intracellular delivery of nanoparticles which are used to destroy the cancer cells. Furthermore, nanoparticles potentially increase the safety of tumor measures and maintain the nano-HAp drug delivery database in tumor-targeting cancer therapy.